Greg Pyszczymuka
Corporate Officer/Principal bei AYTU BIOPHARMA, INC.
Vermögen: 64 661 $ am 30.04.2024
Profil
Greg Pyszczymuka is currently working as the Vice President-Commercial at Neos Therapeutics, Inc. since 2020.
He is also currently serving as the Chief Commercial Officer at Aytu Biopharma, Inc. In terms of education, Mr. Pyszczymuka holds an MBA from Argosy University and an undergraduate degree from Rutgers State University of New Jersey.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AYTU BIOPHARMA, INC.
0,41% | 31.03.2024 | 22 768 ( 0,41% ) | 64 661 $ | 30.04.2024 |
Aktive Positionen von Greg Pyszczymuka
| Unternehmen | Position | Beginn |
|---|---|---|
| AYTU BIOPHARMA, INC. | Corporate Officer/Principal | - |
| NEOS THERAPEUTICS, INC. | Corporate Officer/Principal | 01.11.2018 |
Ausbildung von Greg Pyszczymuka
| Argosy University | Masters Business Admin |
| Rutgers State University of New Jersey | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AYTU BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
